Bluepharma offers an integrated approach on the process of drug development based on novel platforms for the delivery of known drugs, as well as development, manufacturing and commercialization of solid dosage forms.

Bluepharma 基于对已知药物的创新技术平台提供集口服固体制剂研发、生产和上市销售的全过程方案
HIGHLIGHTS

R&D 研究与开发

- Dedicated facilities focused on the development of solid dosage forms, including pre-formulation and formulation studies, analytical methods, scale up, ICH stability and compilation of CMC. 拥有固体制剂研发的专有能力，包括处方前研究、处方工艺研究，分析方法建立及验证、工艺放大、ICH 稳定性研究和 CMC 药品档案的撰写。
- Novel and versatile oral strip formulations, providing solutions for unmet medical needs. 新颖且多样的口服固体剂型，为尚未满足的临床需求提供了解决方案。
- CRO - Clinical pharmacology unit devoted to perform phase 1 clinical trials. 专门从事1期临床研究的临床药理研究的 CRO 机构。

INDUSTRIAL ACTIVITIES 工业化生产

- State-of-the-art manufacturing site for solid dosage forms, approved by USFDA, KFDA, Taiwan FDA and EU authorities. 拥有已通过美国 FDA、欧洲 EMA、韩国 FDA 和台湾 FDA 核准的生产固体制剂的现代化的生产基地。
- Large portfolio covering the main therapeutic areas; export activities worldwide. 拥有覆盖主要治疗领域的丰富产品组合并已出口至全球各地。

COMMERCIALIZATION OF MEDICINES 药品的商业化

- Bluepharma to in-license products/technologies; Bluepharma从中国引进产品/技术许可。
- Bluepharma to serve as a platform for Chinese companies to access EU or/and USA market; Bluepharma为中国制药企业进入欧盟或/和美国市场提供服务平台。
- Bluepharma to out-license proprietary product to Chinese market; Bluepharma将其专有产品的中国市场经营权进行对外许可。
- Bluepharma to provide CRO services to Chinese companies. Bluepharma为中国企业提供 CRO 服务。

BUSINESS OPPORTUNITIES WITH CHINESE PARTNERS: 与中国合作伙伴的商业机会。

- Luzitin focuses on investigating and developing innovative compounds to be used in Photodynamic Therapy (PDT). The selected lead compound on the cancer development program (LUZ11), is currently at phase Ila for advanced Head&Neck cancer. The attributes recognized to LUZ11 constitute important advantages over other photosensitizers as well as to other therapeutic procedures currently available for cancer treatment. The next steps include broadening LUZ11 to other types of solid tumors and completing pre-phase I in a new development program. Luzitin 专注于研究和开发光动力疗法中所应用的创新化合物，肿瘤研究针对脑部和颈部癌的适应症所选中的先导化合物 (LUZ11)，目前处于IIa期的临床阶段。LUZ11 已被证明其特性比其他光敏剂更适用于癌症治疗的其他治疗手段具有重大的优势。下一步行动方案包括拓宽 LUZ11 的适应症到实体瘤和完成预试验 I 期的临床研究。

- TREAT U is dedicated to the development of targeted nanotechnology-based platforms for the specific delivery of drugs (either small drugs or siRNA) with technological advantages that outrun different products commercially available or in clinical trials, namely in the Oncology area. Most visibly, its innovative targeted nanoparticles (PEGASEMP) proved capable of targeting two distinct cell populations in the tumor, the cancer cell and the blood vessels that nurture the tumor. PEGASEMP has recently entered the formal non-clinical program and is set to kick-start clinical trials in 2015 for advanced breast cancer. TREAT U 专注于针对药物（小分子药物或小 RNA 分子）的特定传递技术以靶向纳米技术为基础平台的药物研发，使其技术优势超越在肿瘤领域已上市或正在临床研究的不同产品，最为显著的，其创新的靶向纳米粒子（PEGASEMP）被证明能够针对肿瘤中的两种不同的细胞群，癌细胞和提供肿瘤营养的血管。PEGASEMP 近期已进入正式的非临床程序并定于于2015年启动针对晚期乳腺癌的临床研究。